BIOA

BioAge Labs, Inc. Common Stock
BIOA
Market cap $878M

24.50 USD

+0.38

1.58%

At close Oct 15, 4:00 PM EDT

After hours

24.50

+0.00

0.00%

1 day

1.58%

5 days

9.87%

1 month

20.99%

3 months

20.99%

6 months

20.99%

Year to date

20.99%

1 year

20.99%

5 years

20.99%

About: Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.

–

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for BIOA.

See Analyst Rankings

Financial journalist opinion

Based on 17 articles about BIOA published over the past 30 days

The Motley Fool

GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom

The future of the weight loss market might not revolve around GLP-1 drugs.

GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom

The Motley Fool

Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock

BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm.

Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock

The Motley Fool

2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now

One of these businesses is a risky play, but the other is very likely to succeed.

2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now

24/7 Wall Street

An Airline, Biotechs, and More See Huge Insider Buying

24/7 Wall St. Insights Public offerings of stock and activist investor activity have prompted some huge insider buying.

An Airline, Biotechs, and More See Huge Insider Buying

The Motley Fool

3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October

There's a chance that its lead candidate could become one of the top drugs ever.

3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October

The Motley Fool

This IPO Biotech Stock Could Be the Next Eli Lilly

BioAge has its eyes on a handful of truly gargantuan markets.

This IPO Biotech Stock Could Be the Next Eli Lilly

BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of the Concurrent Private Placement

RICHMOND, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of aging, today announced the closing of its upsized initial public offering of 12,650,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 1,650,000 additional shares, at the initial public offering price of $18.00 per share. All of the shares were offered by BioAge.

BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of the Concurrent Private Placement

BioAge Labs: Weighing The Risks And Rewards Of A Biotech Revival

The biotech sector is reviving, with IPOs reappearing and BioAge Labs' weight loss drug, Azelaprag, showing market potential. Biotech stocks are volatile, facing challenges like regulatory hurdles and high borrowing costs, exacerbated by interest rate hikes. The Federal Reserve's rate cuts have improved borrowing conditions, leading to a surge in biotech IPOs and a 53% rise in biotech stocks since October 2023.

BioAge Labs: Weighing The Risks And Rewards Of A Biotech Revival

U.S. IPO Weekly Recap: 3 Sizable Deals Trade Up

Three IPOs each raised at least $100 million this week, in a welcome bump in activity. Four IPOs and two SPACs submitted initial filings this past week. Six IPOs are currently scheduled to list in the week ahead.

U.S. IPO Weekly Recap: 3 Sizable Deals Trade Up

Investors Business Daily

BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rallies 28% On Upsized IPO

BioAge Labs stock rallied Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity treatments.

BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rallies 28% On Upsized IPO

See News Rankings

Charts implemented using Lightweight Charts™